In patients with type 2 diabetes, pooled incretin-based therapies (GLP-1 receptor agonists and DPP-4 inhibitors) showed no difference in overall pancreatitis risk versus non-users (odds ratio 1.08).
In plain wordsIn people with type 2 diabetes, incretin drugs as a group were not linked to more pancreatitis than no incretin use.
- Peptide
- Liraglutide
- Outcome
- No significant changeAcute pancreatitis risk
- Study
n: not reported in source
- Comparator
- Non-users of incretins
- Outcome group
- Adverse events · Gastrointestinal
Measurements
- Odds ratio, pancreatitis
- 1.08
- incretin users vs non-users
Source sentences
No difference was found in the overall risk of pancreatitis between incretin users and non-users (odds ratio 1.08; 95 % CI [0.84-1.40]).
2 context sentences(design, population, supporting numbers)
Studies were evaluated against the following criteria: design (either cohort or case-control); outcome definition (incidence of pancreatitis); exposure definition (new or current or past incretins users); and comparison between patients receiving incretins or not for type 2 diabetes.
Six studies meeting the inclusion criteria were reviewed.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.